In addition to monitoring for progressive DR with the assistive technologies discussed, prophylactic treatment with anti-VEGF injections should be considered to reduce DR progression
The treatment effect for the primary composite endpoint and its components in Trial 7 are shown in Table 10
Americas obesity epidemic does not seem to be fading, either, with obesity prevalence in the U.S
Abstract The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its incretin effect in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a broader range of physiological effects in the body
The Judicial Panel on Multidistrict Litigation centralized these vision loss cases in the Eastern District of Pennsylvania
Description Retatrutide (LY3437943) is a next-generation triple hormone receptor agonist, also referred to as GLP-3, that simultaneously targets GIP, GLP-1, and Glucagon (GCG) receptors